However, the effects of rs16896059 and rs2449512 on IDC risk were more prominent in patients with tumor size larger than 2 cm, post-menopause, clinical stage 3, low pathological grade, invasion, node infiltration, ER negative, PR negative, Her2 negative, and Ki67 cells less than 10%. This evidence concerns the gene ERBB2 and neoplasm.